Rebus Holdings, Inc. (RBSH) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerRebus Holdings, Inc. (RBSH) trades at $0.0001. Rebus Holdings, Inc. is a biotechnology company focused on developing precision therapeutics for cancer treatment. Their lead asset, RT-AR001, is an adenosine receptor antagonist designed to enhance tumor infiltration. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for RBSH: RBSH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Rebus Holdings, Inc. (RBSH) Healthcare & Pipeline Overview
Rebus Holdings, Inc., a biotechnology firm established in 2003, specializes in the research and development of targeted cancer therapies. Their primary focus is RT-AR001, an adenosine receptor antagonist aimed at improving tumor infiltration. Operating in the competitive biotechnology sector, Rebus Holdings seeks to advance precision medicine for cancer treatment.
What Is the Investment Thesis for RBSH?
Rebus Holdings, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is currently dependent on the successful development and commercialization of its lead asset, RT-AR001. A key value driver is the potential efficacy of RT-AR001 in enhancing tumor infiltration and improving outcomes in cancer treatment. Upcoming clinical trial results for RT-AR001 will serve as a significant catalyst, potentially driving investor interest and stock appreciation. However, the company faces significant challenges, including the need for substantial capital to fund clinical trials and the risk of clinical trial failures. With a small team and limited resources, Rebus Holdings' ability to compete with larger, more established biotechnology companies is a key consideration. The company's high beta of 10.0 indicates significant volatility, reflecting the speculative nature of its stock.
Based on FMP financials and quantitative analysis
RBSH Key Highlights
Rebus Holdings, Inc. is focused on precision therapeutics for cancer treatment.
- The company's lead asset is RT-AR001, an adenosine receptor antagonist.
- RT-AR001 is designed to enhance tumor infiltration when administered intra-tumorally.
- Rebus Holdings was founded in 2003 and is based in Westlake Village, California.
- The company has a market capitalization of $0.00B, reflecting its early stage of development.
Who Are RBSH's Competitors?
RBSH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RBSH's Key Strengths?
Focus on precision therapeutics for cancer.
- Lead asset, RT-AR001, targets a specific mechanism of action.
- Small, agile team allows for focused research and development.
What Are RBSH's Weaknesses?
Limited financial resources.
- Dependence on the success of a single lead asset.
- Small team may lack the expertise and resources of larger companies.
What Are the Key Risks for RBSH?
Clinical trial failures for RT-AR001 could significantly impact the company's valuation.
- Limited financial resources may hinder the company's ability to fund research and development.
- Competition from larger, more established biotechnology companies.
- Regulatory hurdles and delays could delay the commercialization of RT-AR001.
- The company's reliance on a single lead asset increases its vulnerability to setbacks.
What Are RBSH's Competitive Advantages?
- Proprietary technology related to adenosine receptor antagonists.
- Intellectual property protection for its lead asset, RT-AR001.
- Expertise in precision therapeutics for cancer treatment.
What Does RBSH Do?
Founded in 2003, Rebus Holdings, Inc. is a biotechnology company dedicated to the research and development of precision therapeutics for cancer. The company's core focus is on creating innovative treatments that target the specific characteristics of tumors, aiming to improve patient outcomes and reduce the side effects associated with traditional cancer therapies. Rebus Holdings' lead asset is RT-AR001, an adenosine receptor antagonist designed to enhance tumor infiltration and improve the effectiveness of cancer treatments when administered intra-tumorally. Adenosine receptors play a role in suppressing the immune response within tumors, and RT-AR001 aims to block this suppression, allowing the immune system to better target and destroy cancer cells. Based in Westlake Village, California, Rebus Holdings operates with a small team, allowing for focused and agile research and development efforts. The company is committed to advancing its pipeline of precision therapeutics and exploring new approaches to cancer treatment. Rebus Holdings is positioned within the biotechnology industry, which is characterized by rapid innovation, intense competition, and significant regulatory oversight. The company's success depends on its ability to successfully develop and commercialize its lead asset, RT-AR001, and to secure funding for its ongoing research and development activities.
What Products and Services Does RBSH Offer?
- Researches and develops precision therapeutics for cancer treatment.
- Focuses on targeted therapies to improve patient outcomes.
- Develops adenosine receptor antagonists for tumor infiltration.
- Administers treatments intra-tumorally for enhanced effectiveness.
- Aims to reduce side effects associated with traditional cancer therapies.
- Conducts clinical trials to evaluate the safety and efficacy of its therapeutics.
- Seeks regulatory approval for its lead asset, RT-AR001.
How Does RBSH Make Money?
- Focuses on research and development of cancer therapeutics.
- Aims to generate revenue through licensing agreements or partnerships.
- Seeks to commercialize its lead asset, RT-AR001, upon regulatory approval.
What Industry Does RBSH Operate In?
Rebus Holdings, Inc. operates within the competitive biotechnology industry, which is characterized by rapid innovation and intense competition. The industry is driven by the increasing demand for novel therapeutics and advancements in precision medicine. Companies in this sector face significant regulatory hurdles and require substantial capital investments to fund research and development. Rebus Holdings is positioned as a developer of precision therapeutics for cancer, targeting a market with significant unmet needs. Competitors include companies like ANTH, CMRA, FPMI, GBIM, and NLVVF, which are also focused on developing innovative cancer treatments. The success of Rebus Holdings depends on its ability to differentiate its lead asset, RT-AR001, and to secure funding for clinical trials and commercialization.
Who Are RBSH's Key Customers?
- Pharmaceutical companies seeking to license or acquire novel cancer therapeutics.
- Healthcare providers who will administer the company's treatments.
- Patients who will benefit from the company's precision therapies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for Rebus Holdings, Inc. stands at 19.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Rebus Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Westlake Village, US. The company is led by CEO Raul Silvestre. RBSH has traded publicly since 2009.
Financial Health
Rebus Holdings, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
RBSH Financials
RBSH Latest News
No recent news available for RBSH.
RBSH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for RBSH.
Price Targets
Wall Street price target analysis for RBSH.
RBSH MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for RBSH; grades run from A+ (80-100) to F (below 30).
Leadership: Raul Silvestre
Managing Employee
Raul Silvestre is the managing employee of Rebus Holdings, Inc. As the managing employee, he is responsible for overseeing the company's operations and strategic direction. His leadership is critical to the company's success in developing and commercializing its precision therapeutics for cancer treatment.
Track Record: His primary focus is currently on advancing the development of Rebus Holdings' lead asset, RT-AR001, through clinical trials and securing funding for the company's research and development activities.
RBSH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Rebus Holdings, Inc. may not meet the minimum financial standards or disclosure requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity may be sporadic. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and transparency compared to exchanges like the NYSE or NASDAQ. Companies in this tier are often early-stage or distressed businesses.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- High risk of fraud or mismanagement.
- Significant price volatility due to low trading volume.
- Potential for delisting or trading suspension.
- Limited regulatory oversight and investor protection.
- Verify the company's legal status and registration.
- Obtain and review audited financial statements.
- Assess the company's management team and their experience.
- Evaluate the company's business plan and market opportunity.
- Determine the company's capital structure and funding needs.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Company has been in operation since 2003.
- Focus on research and development of cancer therapeutics.
- Lead asset, RT-AR001, targets a specific mechanism of action.
What Investors Ask About Rebus Holdings, Inc. (RBSH) — Healthcare
What do analysts say about RBSH stock?
As of March 16, 2026, there is no available analyst coverage for Rebus Holdings, Inc. due to its OTC listing and small market capitalization.
What are the main risks for RBSH?
The main risks for Rebus Holdings, Inc. include the potential for clinical trial failures for its lead asset, RT-AR001, which could significantly impact the company's valuation.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on limited data available for Rebus Holdings, Inc.
- OTC market investments carry higher risk than exchange-listed stocks.